BRIEF — Sandoz Gets Canada Approval For Generic Semaglutide

Sept 18 (Reuters) — SANDOZ GROUP AG: Sandoz Receives Regulatory Approval For Generic Semaglutide In Canada, Paving Way To Expand Patient Access To Key Glp-1 Medicine Receives Regulatory Approval For Generic Semaglutide In Canada Health Canada Grants Marketing Authorisation For Sandoz Semaglutide Semaglutide Approved In Canada For Once-weekly Injection In Type-2 Diabetes Semaglutide Available In Three Dose Strengths Via Two Pen Presentations In Canada Approval Has No Impact On Sandoz Financial Guidance For 2026 Canadian Glp-1 Market Worth $2.60 Billion With 12 Million Semaglutide Pens Issued Annually Source text:... Further company coverage: SDZ.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 587785269;)